{"id":"W4408236029","doi":"10.1038/s41591-025-03575-0","title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Nivolumab; Ipilimumab; Medicine; Oncology; Randomized controlled trial; Biomarker; Internal medicine; Chemotherapy; Cancer; Immunotherapy; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001524689,0.0003576475,0.002277384,0.0009497453,0.00005581945,0.000007207811,0.0002103788,0.0004174641,0.001180136],"category_scores_gemma":[0.000677054,0.0002160742,0.0004023077,0.001745918,0.0007436215,0.00007815616,0.00002633755,0.0006658376,9.644823e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004013721,"about_ca_system_score_gemma":0.0009890191,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006802084,"about_ca_topic_score_gemma":0.0002221009,"domain_scores_codex":[0.9971001,0.0002856331,0.001198191,0.0004576514,0.0005953991,0.0003629879],"domain_scores_gemma":[0.9983071,0.0005026146,0.0003598282,0.0004921558,0.000228151,0.0001101622],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9027671,0.0005335658,0.0001034526,0.0002443535,0.001254641,0.00009436757,0.0005227391,0.000001092566,0.05035022,0.00002075861,0.01025448,0.03385324],"study_design_scores_gemma":[0.9666753,0.001447297,0.0004681596,0.001583717,0.0007426307,0.00001175315,0.0004478821,0.000396392,0.02494962,0.00004627353,0.003084166,0.0001467434],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8865091,0.09216908,0.0003944702,0.01227085,0.002674012,0.003921,0.00003610332,0.0001030403,0.001922301],"genre_scores_gemma":[0.9881693,0.004817409,0.000187234,0.003916796,0.0005026385,0.0002994199,0.00005771123,0.00003280928,0.002016755],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1016601,"threshold_uncertainty_score":0.9997329,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03941585590825022,"score_gpt":0.4172139224332038,"score_spread":0.3777980665249536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}